Bluejay Investor Presentation Deck slide image

Bluejay Investor Presentation Deck

Symphony™M IL-6 Test: Platform Potential for Rapid Results in Critical Care Settings Quantitative determination of IL-6 by fluorescence enzyme immunoassay from whole blood specimens ●●● DIAGNOSTICS Measuring IL-6 could help medical professionals make earlier and actionable treatment decisions. Rapid turnaround time crucial as 'time is the enemy' in critical care settings. Interleukin-6 (IL-6) is an Early Responder Biomarker During Trauma or Infection. Important in: Sepsis And Covid-19 Cardiovascular Diseases Autoimmune Disorders The SymphonyTM System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Multi-organ-Failure Acute Respiratory Distress Syndrome (ARDS) Infectious Disease Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | November 2023 11
View entire presentation